Spartan Capital Securities, LLC Proudly Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering

In a recent press release in December 2025, Spartan Capital Securities, LLC, announced that it acted as the exclusive placement agent in a $4.3 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing novel cancer therapies.

Lixte Biotechnology entered into definitive agreements with accredited investors for the purchase and sale of Common Stock, along with pre-funded and investor warrants. The transaction was priced at the market in accordance with Nasdaq regulations.

The offering comprised 1,051,342 Common Units and/or Pre-Funded Units. Each Common Unit consisted of one share of Common Stock and one Common Warrant to purchase one additional share of Common Stock at an exercise price of $3.96. Each Pre-Funded Unit included one Pre-Funded Warrant, exercisable at $0.00001 per share, and one Common Warrant. The public offering price was $4.09 per Common Unit and $4.08999 per Pre-Funded Unit. The Common Warrants are immediately exercisable and have a term of sixty months from issuance.

Gross proceeds from the offering are expected to total approximately $4.3 million. The Company intends to use the net proceeds, together with existing cash, for general corporate purposes and working capital.

John Lowry, Chief Executive Officer of Spartan Capital Securities, commented, “This financing reflects our ongoing commitment to delivering customized capital solutions to innovative life sciences companies. Lixte continues to make meaningful progress in oncology, and we are pleased to support the Company during this pivotal phase of development.”

Sichenzia Ross Ference Carmel LLP served as legal counsel to Lixte Biotechnology Holdings, Inc., while Kaufman & Canoles, P.C. acted as counsel to Spartan Capital Securities, LLC.

The registered direct offering was conducted pursuant to an effective shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission and declared effective on May 2, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and made available through the SEC’s website.

About Spartan Capital Securities LLC, Member FINRA/SIPC/MSRB

Spartan Capital Securities, LLC is a full service investment banking firm providing capital markets advisory, capital raising, and strategic advisory services to institutional clients and growth oriented companies. The firm delivers customized solutions aligned with long term client objectives.